PTC Therapeutics shares up 2.01% afterhours due to investigation by Pomerantz Law Firm for potential securities fraud.

Ptc Therapeutics, Inc. experienced a 2.01% increase in after-hours trading following a negative news event. An investigation by Pomerantz Law Firm into potential securities fraud and unlawful practices by the company and its executives has raised concerns among investors. This investigation, announced on June 28th, led to the EMA Committee's negative opinion on PTC's medicinal product, contributing to the stock's post-market upswing. Shareholders who believe they have been affected are encouraged to contact the law firm to explore their legal options.